Study 2 of 25Tirzepatide literatureSemanticScholar2010
Semantic Scholar search for Tirzepatide
Not reported in abstract.
Where it sits
this study against the rest of the tirzepatide corpus4
Preclinical · this one
15
Observational
1
Open-label
2
Randomised
3
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.00). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2010
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Elsewhere in the Tirzepatide corpus
BDual GIP/GLP-1 Receptor Agonist Versus Selective GLP-1 Receptor Agonist in Patients Undergoing Primary Total Knee or Hip Arthroplastybiorxiv-preprint · At 2 years, tirzepatide exposure was associated with lower odds of mechanical complications (OR 0.64, 95% CI 0.42 to 0.96).HumanCTirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese micebiorxiv-preprint · Not reported in abstract.AnimalDThe GLP-1 Nutritional Paradox: A Structured Review with Novel Quantitative Frameworks for Sarcopenic Risk and Micronutrient Adequacy in GLP-1 Receptor Agonist Pharmacotherapybiorxiv-preprint · Mean body-weight reduction of 20.9% with tirzepatide in phase 3 trials.reviewBWeight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weeklybiorxiv-preprint · Mean body-weight loss was 6.10% (95% CI 4.60-7.60; n=8) in the 60-89-day window at a median 65.5 days.HumanCA near-infrared light-triggered platform for on-demand drug release in bone repair.Colloids and surfaces. B, Biointerfaces · 2026 · Bacterial inhibition rate of 99%.In vitroDFrom adiposity to multisystem morbidity: the case for weight loss as disease modification.The lancet. Diabetes & endocrinology · 2026—